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Despite ‘orphan drug’ legislation, bringing new medicines for rare diseases to market and securing funding for their provision
is sometimes both costly and problematic, even in the case of medicines for very rare ‘ultra orphan’ oncological indications.
In this paper difficulties surrounding the introduction of a new treatment for osteosarcoma exemplify the challenges that innovators
can face. The implications of current policy debate on ‘value-based’ medicines pricing in Europe, North America and elsewhere are
also explored in the context of sustaining research into and facilitating cancer patient access to medicines for low-prevalence
indications. Tensions exist between utilitarian strategies aimed at optimising the welfare of the majority in the society and minority-
interest-focused approaches to equitable care provision. Current regulatory and pricing strategies should be revisited with the
objective of facilitating fair and timely drug supply to patients without sacrificing safety or overall affordability. Failures effectively
to tackle the problems considered here could undermine public interests in developing better therapies for cancer patients.
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The Thalidomide tragedy led, in 1962, to amendments to the
United States Food and Drugs Act and subsequently to new UK
and EU legislation on the licensing of medicines. Measures
introduced from that time onwards have required companies to
demonstrate with increasing rigour to external regulators the
safety and efficacy of their products before marketing.
Such reforms, together with developments in areas such as
research methodology, have been associated with substantial
increases in the costs of introducing new medicines. Despite the
productivity and profitability of the research-based pharmaceu-
tical industry in the period 1950–2000, its continuing economic
viability – and arguably that of partner organisations in the public
sector – is today relatively uncertain.
Many authorities now believe that there is a need to review
and where possible simplify and better coordinate all forms of
drug regulation, including for example clinical trial requirements
(Academy of Medical Sciences, 2011). There is also a need to
ensure that price controls and pharmaceutical payer policies are
fully consistent with goals such as those of orphan drug law.
Given the challenges inherent in bringing any new medicine to
market – which when research failures are accounted for, is
estimated to cost over $1000 million per successfully marketed
product (Kaitin and DiMasi, 2011) – it is understandable that
in the past private (and public and voluntary) sector enterprises
often focused their attention on developing and supplying
treatments for diseases that affect relatively large numbers of
relatively affluent people. This left people with rare diseases, or
conditions confined to poor communities, under-served.
However, the advocacy from the 1970s onwards of patients’
organisations such as the United States National Organisation
for Rare Disorders (NORD) (2010) helped to give developing
effective treatments for ‘orphan’ diseases increased priority.
NORD’s lobbying, alongside that of other agencies, was to a
considerable degree responsible for the successful passage through
Congress of the 1983 Orphan Drug Act (ODA).
Further, there are today fewer opportunities for developing new
treatments for common conditions, because of past successes.
Pharmaceutical companies have consequently had little choice but
to become more involved in ‘orphan research’. The full financial
impacts of this may yet to have been realised.
Against this background this paper reviews issues relevant to
ongoing research into medicines for rare and very rare oncological
indications. The introduction of Mifamurtide (MTP), a treatment
for young people with osteosarcoma, exemplifies the difficulties
that could be encountered.
Concerns regarding the proposed introduction of ‘value-based
pricing’ (VBP) for new medicines are also discussed from the
perspective of those seeking to improve treatment for rare
disorders, and for specific aspects of common cancers. As
molecular profiling of the latter identifies increasing numbers of
sub-types, orphan drug legislation will become increasingly
relevant to anti-cancer medicines development.
DEFINING ORPHAN INDICATIONS
The US Orphan Drug Act (ODA) applies to conditions affecting
fewer than 200000 Americans. This currently translates to
approximately 7 per 10000 individuals. It offers manufacturers
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and additional regulatory advice and tax benefits.
There are in total over 5000 rare diseases, about 80% are genetically
based (EURODIS, 2010). They at present collectively affect some
25 million North Americans and in the order of 30 million European
Union citizens (Committee for Orphan Medicinal Products, 2011).
The ODA was followed by similar provisions in Singapore
(1991), Japan (1993), Taiwan and Australia (1998). The EU
eventually followed suit in 2000, with a Directive that justified a
special status for orphan drugs on the basis of equity. It stated that
‘patients suffering from rare conditions should be entitled to the
same quality of treatment as other patients’. In the EU, orphan
conditions are considered to have a prevalence of less than 5 cases
per 10000 of population. The European provisions offer up to 10
years of market exclusivity, together with other forms of support.
The ODA has been called ‘the most successful legislative action
in recent US history’ (Haffner, 2006). The available evaluations
indicate that it has successfully encouraged pharmaceutical
innovation and offers a robust model of how public policy can
stimulate research and development when candidate technologies
are otherwise likely to generate inadequate private returns.
The European legislation has also been of value. It may
sometimes have caused treatments that were in practice already
in use for ‘off-label’ indications to be offered in better formulated
and evidenced, but also more expensive, presentations. However,
innovative products and applications have unquestionably resulted.
Examples of therapeutic developments that have received orphan
drug designation range from Riluzole for motor neurone disease
(ALS) to Temozolomide for malignant gliomas.
In the period between the adoption of the EU legislation in
2000 and the end of 2010, a total of 63 designated orphan
medicines received marketing authorisation. Some 40% were for
oncology indications (Committee for Orphan Medicinal Products
and the European Medicines Agency Scientific Secretariat, 2011).
However, in the individual EU Member States the availability of
these treatments varies from over9 0 %b e i n gr e i m b u r s e dt ou n d e r
30% (Le Cam, 2011).
BRINGING DRUGS FOR ORPHAN INDICATIONS TO
MARKET
Osteosarcoma is the most common primary malignant tumour
occurring in bone. Yet, it has an incidence of only 2.5–4 cases
per million total population (Mirabello et al, 2009). It therefore
falls under the NICE definition of a very rare ‘ultra orphan’
disease, as it affects less than 1000 people in the United Kingdom.
There are less than 1000 new cases diagnosed each year in the US
and about 1500 in the EU (Figure 1).
Even with surgery and multiple chemotherapy, the prognosis for
patients with osteosarcoma is relatively disappointing. In the
region of 60–70% of patients are cured of localised osteosarcoma.
However, those diagnosed with metastatic disease have seen little
recent progress. The long-term event-free survival rate is less than
30% (Kager et al, 2010).
Mifamurtide is a relatively new medicine for people with
osteosarcoma. It was granted orphan drug designation by the FDA
in 2001 and by the European Medicines Agency (EMEA) in 2004.
Its to date partial introduction exemplifies the barriers that the
makers of orphan cancer medications may have to overcome
during the drug development and supply process.
Once a potentially useful new treatment has been identified,
clinical trials must be undertaken. Trial design for drugs for
orphan diseases is often (primarily because of their infrequency)
hindered by a lack of data on disease progression, poor diagnostics
and inadequately defined clinical endpoints. In addition, the rarity
of conditions such as osteosarcoma makes recruiting sufficiently
large numbers of patients inherently difficult and expensive.
In the case of MTP, the evidence needed to support a successful
European marketing application was derived from a trial called
the Intergroup Study 0133. This was the largest ever randomised
trial in osteosarcoma. It recruited in total nearly 800 US patients
aged less than 31 years and took 5 years (1993–97) to gain suffi-
cient numbers (Meyers, personal communication). It involved a
substantial investment by the US National Cancer Institute.
In outline, all patients in the study received ‘backbone’
treatment using Cisplatin, Doxorubicin and Methotrexate. The
addition of MTP resulted in a statistically significant improvement
in survival. In absolute terms, the latter increased from 70 to 78%
at 6 years (Meyers et al, 2008; Meyers, 2011). The great majority of
these individuals live on without disease re-occurrence (Kager
et al, 2010).
However, Intergroup 0133’s findings were originally presented
to the FDA with 3-year follow-up data (Meyers et al, 2005). Because
of concerns about the statistical approach and findings offered at
that time MTP was denied FDA approval in 2007. (Licensing
refusal is a not uncommon outcome in the orphan drugs context.
Joppi et al (2009) found the success rate for applications to
be 63%, compared with over 70% for drugs for non-orphan
indications.) The Administration requested an additional clinical
trial. Yet, organising this would be both expensive and difficult
given that in 2005 another major osteosarcoma trial – the
EURopean-American Osteosarcoma Study (EURAMOS) – had
begun recruitment.
Further evidence of the effectiveness of MTP, based on
Intergroup Study 0133 with 6-year follow-up data and a more
robust statistical analysis, was submitted to the EU’s EMEA in
2009. As a result MTP now has a marketing authorisation in all 27
Member States, together with Iceland, Liechtenstein and Norway.
However it remains unlicensed in the United States.
Even in Europe, osteosarcoma patient access to MTP is variable.
Although it is now reimbursed by health-care funders in countries
such as Germany, Spain, Italy and Austria, this is not the case in,
for instance, France. In the UK NICE has, following a revision in
its assessment model, recently approved MTP as cost-effective for
NHS use for osteosarcoma. But this was nearly 30 months after it
was accepted as effective and safe by the EMEA (National Institute
for Health Clinical Excellence, 2011).
The MTP example thus shows that even when an orphan drug is
licensed it may still in practice be unavailable to those patients
unable to pay, or able to obtain it via trial participation. From
patients’, clinicians’ and pharmaceutical investors’ perspectives
there is a need for more consistent policies towards and decisions
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Figure 1 Estimated osteosarcoma incidence in selected countries. On
the basis of a mean incidence three case per million using the World Bank
and EUROSTAT population figures for 2010.
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and for better coordination of regulatory and payer policies.
Given current trends towards more ‘personalised’ treatments,
there is from a cancer care viewpoint a danger that failures to
resolve tensions between equity-based orphan drug legislation on
the one hand and more restrictive ‘NICE type’ utilitarian approaches
to drug pricing and reimbursement on the other will, in addition to
causing individual injustices, over time inhibit therapeutic improve-
ment. This could prove contrary to not only patient wishes but also
to long-term social and economic public interests.
FAIR DRUG ACCESS AND SUSTAINABLE
INNOVATION
Costing medicines development is controversial. This is in part
because of issues such as the extent to which expenditures on
failed research should be attributed to successfully marketed
treatments. Regarding ‘orphan drugs’, there is a lack of definitive
empirical research. However, it is realistic to conclude that although
(depending on the accounting conventions used, and phase 3 costs
incurred) such medicines may for individual indications normally
be less costly to develop than treatments for prevalent conditions,
their unit costs will be significantly higher.
This means that drugs for rare indications will typically be much
more expensive per course provided and unit of welfare gained
than similarly effective medicines for common complaints. If in
cases such as that of MTP the fact that conducting adequately
powered trials can be unusually costly is also taken into account
this asymmetry will be further amplified.
Such observations provide powerful reason for where possible
minimising the cost of pre-market trial requirements in the orphan
and ultra-orphan drug licensing contexts, and for questioning
approaches such as that to date taken by the FDA in the context of
MTP. In this particular instance it could have been feared that the
viability of the EURAMOS trial of established therapies would be
impaired if more osteosarcoma patients were able to access MTP
(Bielack, 2010). But this would be a perverse reason for delaying
marketing approval for MTP, given the robust evidence of young
adult survival advantage available.
Such concerns support the further acceptance of the ‘coverage
with evidence development’ model now gaining traction in the
United States (Cohen, personal communication). ‘Orphan drugs’
can only become successful medicines if they are provided to
patients who benefit from them. Failures to agree adequate and
timely reimbursement provisions undermine the well-being of
individuals who have uncommon treatment needs and risk research
and development investments. At the same time they do not always
save the overall community money. This is partly because (as indi-
cated earlier) the costs of ‘marketing failures’ must ultimately be
loaded onto successful products, if private sector-funded research
and development is to generate levels of profitably sufficient to
incentivise ongoing investment. Some medicines designated as
orphan products, perhaps most notably Glivec/Gleevec, have
proved highly profitable. However, organisations such as Eurordis
have warned against unwarranted extrapolations based on such
exceptional instances (Le Cam, 2011).
It can in addition be argued that innovation in areas such as
oncology is best seen as a single extended process, rather than a
series of separate, fragmented steps. At some stages the rate and
scale of progress may be disappointing. But when most, if not all,
cancers can be prevented, cured or successfully contained, the
long-term benefits to humanity will in all probability far outweigh
the aggregated development costs of the individual technologies
involved.
To put the current financial burdens imposed by orphan medicines
into context, they have been estimated to represent in the order of
1–2% of national medicine budgets (or 0.01–0.03% of GDP) in
European countries (Orofino et al, 2010). With regard to oncology,
the United States – the world’s largest user of anti-cancer
drugs – spent about 0.2% of its national wealth on anti-cancer
medicines in 2010 (Catchpole and Taylor, 2011). This represents a
significant but not unaffordable sum. The proportion of GDP
spent on anti-cancer treatments in other OECD nations is
typically lower.
Some commentators have warned that new ‘cancer medicine’
costs could in future impose unsustainable burdens on health
services. But when factors such as the impacts of established
oncology (and other) treatment patent expiries and increased
payer reluctance to accept high-unit cost medicine prices (even in
environments such as the US – see Hyde and Dobrovolny, 2010)
are factored in, such concerns appear at best exaggerated. It is
more probable that the financial sustainability of private sector
medicines research in fields such as oncology will become
increasingly fragile, unless measures are taken to offset this hazard.
In fact, although treatments for uncommon indications are
expensive at the individual episode of care level, their rarity
limits their total cost even where high-unit prices are permitted.
Current European, US and international policy debate on VBP for
medicines should take this and other caveats into account.
Relevant proposals involve relating the maximum ‘affordable’
prices of pharmaceutical innovations to the cost of the additional
quality-adjusted life years (QALYs) they provide. The theoretical
strengths and weaknesses of this approach cannot be detailed
here. However, with regard to medicines for rarer indications,
it is worth emphasising that the crude application of utilitarian
approaches that favour funding research and treatments for
common disorders could become a major barrier to further
progress in cancer treatment.
Enhanced understandings of disease mechanisms may in future
allow more anti-cancer drugs to be developed as treatments for
several orphan indications in ways which may in overall terms
prove highly profitable, despite the imposition of relatively low
‘cost per QALY’ affordability thresholds. Yet, there will be many
instances when this is not the case.
Some influential participants in the current policy debate
recommend that ‘cost per QALY’-based approaches to medicine
pricing should make no special allowances for factors such as
indication rarity (McCabe et al, 2005). However, Drummond et al
(2007) have aptly asked ‘why have incentives to develop (orphan)
drugs if they will later be judged by criteria on which they are
doomed to fail?’
CONCLUSION
During the last half-century governments and agencies across
the world have increased their requirements for assuring the
safety and efficacy of medicines. They have also put in place
arrangements for encouraging the development of drugs for rarer
oncological and other conditions. These have in many respects
been successful. But in some instances, obtaining a marketing
authorisation is needlessly challenging and costly. Enabling
valuable medicines to be accepted for normally reimbursed use
can be even more difficult.
There is a danger that political and regulatory approaches to
assuring safety and ‘cost effective’ medicine prices will offset the
intended impact of ‘orphan drug’ policies. Such mismatches could,
if unresolved, seriously undermine both privately and publicly
funded medical and pharmaceutical research in oncology.
Protecting patients and communities from unacceptable drug
side-effects – such as the teratogenic consequences of inappropri-
ate Thalidomide use – is a vital priority. However, if public and
patient interests are to be served efficiently, unnecessary
regulatory costs and restrictions should be avoided. Safety at any
cost is not a desirable policy objective.
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social justice and value for money in health care should also seek
to ensure that when treatments for rare conditions are licensed
they are, notwithstanding the conflicts of interest surrounding
medicines pricing, rapidly accepted for reimbursement. Pharma-
ceutical payers’ policies should be aligned with those of other
agencies seeking to defend legitimate public interests in, and
beyond, the health sector.
There is hence a powerful case for concluding that even if there
is less than complete knowledge of an orphan drug’s profile at the
time of a marketing application, the most equitable future approach
will typically be to grant a conditional license and to monitor the
medicine’s value in normally funded use. To permit this disputes
about the initial prices of new treatments should be resolved in
ways which neither needlessly delay patient access to them nor
undermine the confidence of research investors. In the final
analysis ‘excess’ profits can be repaid. Lost lives cannot.
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